The Pharma Letter4h
Lilly reports better than expected earnings
US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...
The Pharma Letter7h
Kura to take AML drug ziftomenib to regulators after mid-stage win
Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...
The Pharma Letter7h
Positive results for Qlaris Bio’s eye drug QLS-111
US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials ...
The Pharma Letter18h
FDA nod at last for Supernus’ Parkinson’s infusion therapy
It is fourth time lucky for Supernus Pharmaceuticals, as its Parkinson’s specialist finally receives US approval for Onapgo ...
The Pharma Letter4h
Markets acknowledge AstraZeneca’s forecast-busting numbers
Anglo-Swedish pharma major AstraZeneca beat analyst expectations in presenting its impressive latest financial results.
The Pharma Letter6h
Ultragenyx updates on UX111 AAV gene therapy
California, USA-based rare disease company Ultragenyx Pharmaceutical yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a statistically-significant ...
The Pharma Letter7h
NEJM publishes Bizengri data after speedy FDA nod
The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. Bizengri is the first approved treatment for people ...
The Pharma Letter7h
ICER evidence report on Vertex new treatment for acute pain
US health technology assessor the Institute for Clinical and Economic Review (ICER) yesterday posted its revised Evidence Report assessing the comparative clinical effectiveness and value of ...